Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

NEPTUNE I and II data on tamsulosin/solifenacin presented

Oct. 22, 2012

Phase II and III studies of bardoxolone methyl suspended

Oct. 19, 2012

Researchers describe activity of TAC-302

Oct. 19, 2012

Mitsubishi Tanabe and Kureha complete EPPIC phase III studies

Oct. 10, 2012

Encouraging follow-up data emerges from phase IIb PRX-302 study

Oct. 10, 2012

AstraZeneca and Ardelyx sign licensing deal for NHE-3 inhibitor program

Oct. 10, 2012

Mirabegron safe in male patients with bladder outlet obstruction

Oct. 8, 2012

Bayer Yakuhin seeks additional approval for Fosrenol chewable tablets and granules in Japan

Oct. 5, 2012

Votubia recommended for approval in Europe

Sep. 26, 2012

CHMP gives positive opinion on Cialis in new indication

Sep. 26, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 14, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Alzheimer’s, beyond the brain
BioWorld
Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...